Introduction
Continuous fetal heart rate (FHR) monitoring coupled with intermittent microsampling of fetal capillary blood for acid-base status is one of the objective methods for the evaluation of the effects of a pharmacologic agent on the fetus. Prior to the availability of these techniques, neonatal outcome was the only parameter available to test the effect of a pharmacologic agent on the fetus in clinical practice. FHR variability as seen in a FHR tracing is a clinical indicator of the fetal neurocardiovascular integration [11] . Various drugs have been demonstrated to alter FHR variability [4, 12, 13, 16] . A close approximation of human fetal oxygenation can be measured continuously with the use of a transcutaneous osygen electrode during the active phase of labor [8] . Although HUGH et al. [7] have reported a decline in human maternal tcPoi following the administration of 50 or 100 mg meperidine intramuscularly, fetal tcPoi was not measured. L FGREN reported that FHR variability lags behind transcutaneous Ρθ2 (tcPo2) changes by some time [10] . The purpose of this study is to evaluate the relationship of fetal oxygenation to FHR variability and uterine activity following the maternal administration of 50 mg intravenous meperidine and to describe the temporal relationship of alterations in FHR variability to changes in fetal tcPo2 and uterine activity in the human.
Patients and procedures
Ten patients from the Sloane Hospital for Women at the Columbia-Presbyterian Medical Center in New York underwent tcPo2 evaluation of fetal oxygenation, fetal heart rate variability and uterine activity. All patients in this study were in the active phase of uncomplicated labor, maintaining one position with cervical dilatation between three and eight centimeters at the onset of the study. The demographic characteristics of these patients are given in table I. No patient received any medi- (7) (8) (9) (10) cation, with the exception of oxytocin which when used was infused at a constant rate throughout the evaluation period. The dosage and timing of meperidine administration was determined by the managing obstetrician using standard clinical indicators. Patients were monitored using an FHR electrode and an intrauterine catheter. Uterine activity was measured by an open ended transcervical intrauterine catheter connected by a strain gauge placed at the level of the patient's sternum and quantitated either with Montevideo units or by measuring the area under the uterine pressure curve (uterine activity units) with an on-line technique utilizing a voltage control oscillator [6] .
Fetal oxygenation was measured continuously by a transcutaneous Ρθ2 (tcPoi) electrode in ten patients in the manner described by HUGH [8] .
The tcPoa measurements are based on the polarographic technique by which the skin is warmed to 43 °C and a deflection in the current between platinum cathode and silver anode, caused by molecular oxygen diffusing from the fetal epidermis, is recorded as tcPoi (Oxymonitor, Litton Co., Chicago). These electrodes are in an electrolyte solution and covered by a teflon membrane which is permeable to oxygen and in contact with the tissue from which tcPo2 is to be measured [3, 5] . The validity of this technique in this laboratory has been established by comparing tcPo2 values with fetal scalp capillary Ρθ2 and umbilical arterial and venous Ρθ2 values [1] .
Following shaving of the fetal scalp, the tcPo2 electrode was applied to the presenting part with an histoacrylic glue. The tcPo2 electrode was appropriately calibrated prior to uSe, and at the termination of the observation period, tcPo2 was correlated with either the capillary Ρθ2 value or with Ρθ2 from umbilical arterial or venous blood whenever possible. After stabilization of tcPo2 readings, a control or preinjection measurement and recording were obtained. Meperidine was then administered intravenously over a two-minute interval.
From the ten patients in New York, the interval from the injection to the onset of decline and the maximum decline in tcPo2 levels were recorded. The duration of the maximum decline in tcPo2 and the interval for a return to a recovery baseline were also observed. The differential index (DI) or short-term variability (the standard deviation of the sequential "R-R" interval differences) and the interval index (II) or long-term variability (the coefficient of variation of the standard deviation of the "R-R" intervals) in sequential fifteen second windows within each five minute segment were averaged and expressed as the mean DI and II for that fiveminute segment of baseline FHR. The five-minute averaging process was repeated every five minutes for a one-half hour pre-injection period and for the duration of the measured post-injection period. Finally the mean value of each index for each of the five-minute time segments was then calculated for the group of twenty patients.
Uterine activity (torr minutes, uterine activity units) was summed for each ten-minute interval of the preinjection and postinjection period. Linear regression analyses of the pre-and postinjection data for uterine activity was utilized to compare the differences of slopes between expected uterine activity and the actual observed uterine activity.
Results
Fetal oxygenation measurements (tcPo2) from the ten New York patients who received 50 mg intravenous meperidine are presented in table II. In these patients the mean preinjection baseline tcPo2 was 18.6 torr. A decline in tcPo2 was noted at 3.13 minutes following the injection. The mean maximum decline value in tcPo2 (11.7 torr) which lasted for an average of 4.5 minutes, was noted 9 minutes after the injection. This decline was statistically significant (t test, P < 0.01). The mean recovery baseline tcPo2 of 15.0 torr was reached after an average of 15.29 minutes, ± 7.68 from the onset of the injection. There was a direct correlation between injection to onset of decline interval and the duration of maximum decline (r = 0.75); as well as between duration of maximum decline and baseline recovery (r = 0.85).
The visually evaluated FHR variability data (from New York) was compared to the computer derived data (from the California patients) and were found to correlate almost identically. A similar correlation was found for uterine activity data measured in Montevideo units and uterine activity units.
The mean fifteen second window representing the first five minute segment of baseline long-and short-term variability following the injection of meperidine was noted to rise slightly, and the second five-minute interval began to decrease which continued for each five-minute interval until a maximum depth was reached at 25 minutes with a return toward normal values by 30 minutes postinjection.
The decline in tcPo2 and a transient increase in FHR variablity (followed immediately by decrease in the indices of FHR variability), after the injection of meperidine is associated with a decrease in uterine activity which is different from the normal positive slope curve of unmedicated uterine activity. This shift in uterine activity is significant (P < 0.05, paired "t" test). The temporal relationship of fetal tcPoz, baseline long and short term variability (quantitated computer derived indices) and uterine activity following the injection of 50 mg of intravenous meperidine are given in figure 1 .
The tcPo2 values, FHR variability indices, and uterine activity changes in one patient receiving 75 mg of intravenous meperidine were similar to those obtained in patients receiving 50 mg meperidine; however, no changes in tcPo2 were noted in two patients who received 25 mg intravenous meperidine. 
Discussion
These data indicate that there is a decline in fetal tcPo2 values shortly following intravenous injection of 50 mg meperidine. The lowest level of oxygenation is noted approximately seven minutes following the beginning of the injection. The duration of maximum decline lasts for approximately five minutes, and the tcPo2 shortly returns to a recovery baseline at a slightly lower level than the preinjection oxygenation value. Analysis of FHR variability indicates that there is a decrease in short and long term indices of FHR variability which is noted at the 10 minute postinjection interval following a short increase in indices at 5 minutes between five and ten minutes following the injection. This decline lasts for approximately 15 minutes with an initiation of return toward normal baseline levels at 30 minutes postinjection. Uterine activity is noticed to decrease almost immediately following the intravenous injection of 50 mg of meperidine. This suggests that changes in fetal tcPo2 values precede those in FHR variability. Although a decrease in maternal oxygenation following meperidine injection has been reported by HUGH et al. [7] , the correlation between FHR variability, fetal tcPo2 changes and uterine activity have not been reported.
The mechanism for the transient fall in fetal oxygenation is not well understood. Inasmuch as abnormal umbilical cord positioning and FHR variable decelerations were noted in a number of patients, some meperidine induced exaggeration in the reflex mediated release of acetyl choline at the fetal sino-atrial node may be considered as a potential mechanism. Constriction of the uterine vasculature or fetal peripheral vasoconstriction due either to the drug or fetal hypotension can also represent possible etiologies. HUGH et al. [7] demonstrated that there is a relationship between the administration of meperidine and a decrease in maternal respiratory effort. Perhaps this may be a possible contributor to a decline in fetal tcPoa, when observed; maternal emesis can be an additonal factor.
The slight increase in indices of FHR variability at five minutes postinjection probably represents an alteration in the Po2/Pco2 relationship. This change most probably is mediated by the barochemoreceptors. This pattern of shift in FHR variability with fetal hypoxia was first described by STANGE et al. [14] and later supported by other investigators including MILLER et al. [12] .
No additionally significant FHR changes other than in indices of FHR variability were noted in these patients nor were there any shifts of perinatal morbidity secondary to this transient change in oxygenation. In contrast to a longer temporal interval of transient decrease in fetal tcPo2 levels which are seen with paracervical block [2] , the transient decrease in tcPo2 following meperidine injection was not felt to have clinical significance; nevertheless, in management of fetuses with borderline oxygenation, this observation should be considered, particularly when other procedures and techniques are utilized in which synergy could lead to clinically overt fetal hypoxic problems. A significant decline in fetal tcPo2 seen in some patients may be due to peripheral vasoconstriction resulting from elevated fetal catecholamines or for technical reasons due to caput and moulding of fetal head and/or compression of electrode in advanced labor [9] .
The use of quantitated FHR variability from a second but demographically matched and identically managed group of patients was of major assistance to demonstrate quantitation of FHR data only. The changes in FHR variability data had already been appreciated visually, the quantitated data were used to enhance the demonstration of the tcPo2-FHR variability relationship.
The analysis of uterine activity data by both methods demonstrated a diminution following the intravenous injection of 50 mg of meperidine. This indicates that the transient decrease in fetal oxygenation following meperidine injection is probably not due to decreased intervillous space blood flow secondary to increased uterine activity, although this possibility cannot be totally eliminated since approximately 10 percent of the patients have been observed to have an increase of uterine activity following the injection of this dose of meperidine.
For completeness, intravenous doses of 25 mg and 75 mg of meperidine has been evaluated using this protocol in a few patients. Meperidine 25 mg administered intravenously causes no change in tcPo2 readings and only very minimal changes in FHR variability and uterine activity. Changes very similar to, but somewhat more pronounced, than those described for 50 mg intravenous meperidine wer recorded when meperidine 75 mg was administered intravenously.
Summary
Fetal tcPoz levels were measured in 10 patients following maternal administration of 50 mg of meperidine by intravenous route. About 3 minutes following injection of meperidine, tcPo2 values started to decline to reach the lowest value of 37 ± 25% by 7 mins of injection. tcPoz values recovered by about 15 mins following injection. These changes in fetal tcPo2 levels preceded transient minimal increase in FHR variability. The increase in FHR variability was followed immediately by a decrease in the indices of the FHR variability. The uterine activity began to decline below the predicted positive slope values shortly following injection of meperidine. This decline was maximum 15 mins post-injection, subsequently establishing a trajectory toward the positive values expected for unmedicated labor. Two patients receiving 25 mg intravenous meperidine demonstrated no decline in tcPo2 levels; however, in the patient receiving 75 mg of intravenous meperidine, the changes noted were similar to those observed following 50 mg of meperidine.
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